NCT06557096View on ClinicalTrials.gov

CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

August 20, 2024

Primary Completion Date

June 1, 2027

Study Completion Date

July 31, 2028

Conditions

Non Small Cell Lung CancerCirculating Tumor CellEGF-R Positive Non-Small Cell Lung Cancer

Interventions

DRUG

Osimertinib 80 MG

Osimertinib is taken orally at a dose of 80mg daily for a 28-day treatment period, followed by a sequential treatment of osimertinib 80mg daily taken orally for another 28 days.

DRUG

Bevacizumab

Sequential combination therapy with bevacizumab administered intravenously at a dosage of 7.5mg/kg of body weight on the first day of each cycle, with medication given once every 3 weeks, for a continuous treatment duration of 21 days.

All Listed Sponsors

lead

Second Affiliated Hospital of Nanchang University

OTHER

NCT06557096 - CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC | Biotech Hunter | Biotech Hunter